Dina Schneider

机构：Lentigen Technology (United States), Cara Therapeutics (United States) · ORCID：0000-0001-7130-7374

发表论文 119 篇 · 总被引 3386 次 · h-index 25

代表论文

• Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1 (2024 · Journal for ImmunoTherapy of Cancer · 被引 23)
• Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma (2025 · Nature Communications · 被引 17)
• BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial (2026 · Nature Medicine · 被引 15)
• Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma (2025 · Journal of Clinical Oncology · 被引 14)
• Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL (2025 · EBioMedicine · 被引 11)
• Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (2024 · JAMA Oncology · 被引 10)